Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AstraZeneca's Imfinzi, a PD-L1 Immunotherapy, Approved in China for NSCLC

publication date: Dec 13, 2019

AstraZeneca was authorized to market Imfinzi (durvalumab), its PD-L1 immunotherapy, in China as a treatment for patients with unresectable, Stage III non-small cell lung cancer (NSCLC). In the drug's Phase III trial, 57% of Imfinzi patients were alive at the three-year mark compared with 43.5% for placebo. Also, the median progression free survival was 16.8 months for Imfinzi against 5.6 months for placebo.. So far, China has approved five PD-1 drugs, but Imfinzi is the first PD-L1 candidate to enter the market. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here